All In Biotech

Drug Trial Radar · NCT07437950

Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

A Randomized Phase II Trial of ASTX727 With Standard Duration Versus Shorter Duration of Venetoclax in Genomically Heterogenous AML Among Adults Aged 60 or Older and Less Fit for Intensive Therapy: A MyeloMATCH Substudy

Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

126

Planned (sponsor's estimate)

Start

Sep 25, 2026

Primary completion

Sep 22, 2034

Study completion Sep 22, 2034

Sponsor

Sponsor type
NIH
First posted
Feb 27, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase II MyeloMATCH treatment trial compares ASTX727 with standard duration versus shorter duration of venetoclax for the treatment of newly diagnosed acute myeloid leukemia (AML). ASTX727 is a combination of decitabine and cedazuridine. Decitabine is in a class of medications called hypomethylation agents. It works by helping the bone marrow produce normal blood cells and by killing abnormal cells in the bone marrow. Cedazuridine is in a class of medications called cytidine deaminase inhibitors. It prevents the breakdown of decitabine, making it more available in the body so that decitabine will have a greater effect. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Shorter duration venetoclax may be as effective as standard duration venetoclax when given with ASTX727 for the treatment of newly diagnosed AML.

Conditions

  • Acute Myeloid Leukemia

Interventions

  • Biospecimen CollectionProcedure

    Undergo blood sample collection

  • Bone Marrow AspirationProcedure

    Undergo bone marrow aspiration

  • Decitabine and CedazuridineDrug

    Given PO

  • VenetoclaxDrug

    Given PO

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Minimal residual disease (MRD) negative complete remission (CR)Time frame: At 180 days

Locations

83 sites in 2 countries. Site status is shown where the registry gives one.

  • Kootenai Health - Coeur d'Alene

    Coeur d'Alene, Idaho · Recruiting

  • Kootenai Clinic Cancer Services - Post Falls

    Post Falls, Idaho · Recruiting

  • Kootenai Clinic Cancer Services - Sandpoint

    Sandpoint, Idaho · Recruiting

  • Illinois CancerCare-Bloomington

    Bloomington, Illinois · Recruiting

  • Illinois CancerCare-Canton

    Canton, Illinois · Recruiting

  • Illinois CancerCare-Carthage

    Carthage, Illinois · Recruiting

  • Northwestern University

    Chicago, Illinois · Recruiting

  • University of Chicago Comprehensive Cancer Center

    Chicago, Illinois · Recruiting

  • Carle at The Riverfront

    Danville, Illinois · Recruiting

  • Cancer Care Specialists of Illinois - Decatur

    Decatur, Illinois · Recruiting

  • Decatur Memorial Hospital

    Decatur, Illinois · Recruiting

  • Carle Physician Group-Effingham

    Effingham, Illinois · Recruiting

  • Illinois CancerCare-Eureka

    Eureka, Illinois · Recruiting

  • Illinois CancerCare-Galesburg

    Galesburg, Illinois · Recruiting

  • Illinois CancerCare-Kewanee Clinic

    Kewanee, Illinois · Recruiting

  • Illinois CancerCare-Macomb

    Macomb, Illinois · Recruiting

  • Carle Physician Group-Mattoon/Charleston

    Mattoon, Illinois · Recruiting

  • UC Comprehensive Cancer Center at Silver Cross

    New Lenox, Illinois · Recruiting

  • Cancer Care Center of O'Fallon

    O'Fallon, Illinois · Recruiting

  • HSHS Saint Elizabeth's Hospital

    O'Fallon, Illinois · Recruiting

  • University of Chicago Medicine-Orland Park

    Orland Park, Illinois · Recruiting

  • Illinois CancerCare-Ottawa Clinic

    Ottawa, Illinois · Recruiting

  • Illinois CancerCare-Pekin

    Pekin, Illinois · Recruiting

  • Illinois CancerCare-Peoria

    Peoria, Illinois · Recruiting

  • Illinois CancerCare-Peru

    Peru, Illinois · Recruiting

  • Illinois CancerCare-Princeton

    Princeton, Illinois · Recruiting

  • Southern Illinois University School of Medicine

    Springfield, Illinois · Recruiting

  • Springfield Clinic

    Springfield, Illinois · Recruiting

  • Springfield Memorial Hospital

    Springfield, Illinois · Recruiting

  • Carle Cancer Center

    Urbana, Illinois · Recruiting

  • Illinois CancerCare - Washington

    Washington, Illinois · Recruiting

  • UChicago Medicine Northwest Indiana

    Crown Point, Indiana · Recruiting

  • University of Kentucky/Markey Cancer Center

    Lexington, Kentucky · Recruiting

  • LSU Health Baton Rouge-North Clinic

    Baton Rouge, Louisiana · Recruiting

  • Our Lady of the Lake Physician Group

    Baton Rouge, Louisiana · Recruiting

  • Trinity Health IHA Medical Group Hematology Oncology - Brighton

    Brighton, Michigan · Recruiting

  • Trinity Health IHA Medical Group Hematology Oncology - Canton

    Canton, Michigan · Recruiting

  • Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital

    Chelsea, Michigan · Recruiting

  • OSF Saint Francis Hospital and Medical Group

    Escanaba, Michigan · Recruiting

  • Trinity Health Saint Mary Mercy Livonia Hospital

    Livonia, Michigan · Recruiting

Showing 40 of 83 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.